Mr. Steinberg stated, “Pacira remains one of the rare ‘hyper growth’ stories in life sciences — with stellar execution leading to Exparel annualizing at $180M (just 1.6 percent share) after nine quarters.”
Pacira Pharmaceuticals’ shares closed yesterday at $101.85.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
